These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25590956)

  • 1. Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system.
    Biscaglia S; Secco GG; Tumscitz C; Di Mario C; Campo G
    Int J Cardiol; 2015 Mar; 182():1-3. PubMed ID: 25590956
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry.
    Imori Y; D'Ascenzo F; Gori T; Münzel T; Fabrizio U; Campo G; Cerrato E; Napp LC; Iannaccone M; Ghadri JR; Kazemian E; Binder RK; Jaguszewski M; Csordas A; Capasso P; Biscaglia S; Conrotto F; Varbella F; Garbo R; Gaita F; Erne P; Lüscher TF; Moretti C; Frangieh AH; Templin C
    Cardiol J; 2016; 23(4):374-83. PubMed ID: 27515481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary Artery Aneurysm After Bioresorbable Scaffold Implantation in a Woman With an Acute Coronary Syndrome.
    Cereda AF; Canova PA; Oreglia JA; Soriano FS
    J Invasive Cardiol; 2017 Jul; 29(7):E77-E78. PubMed ID: 28667808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.
    Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Röther J; Tröbs M; Schlundt C; Achenbach S; Hamm CW; Nef HM
    Clin Res Cardiol; 2017 Apr; 106(4):271-279. PubMed ID: 27757522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and Mid-Term Vascular Responses to Optical Coherence Tomography-Guided Everolimus-Eluting Stent Implantation in Stable Coronary Artery Disease.
    Shinke T; Itoh T; Ishida M; Otake H; Terashita D; Fusazaki T; Kikuchi T; Okamura T; Morita T; Hayashi T; Sawada T; Yasaka Y; Inoue T; Matsuura A; Kawata M; Kozuki A; Shite J; Kataoka T; Hibi K; Ishihara S; Akasaka T; Kubo T; Ino Y; Sonoda S; Furuya J; Sugaya T; Shibata Y; Kuriyama N; Igarashi N; Matsumoto D; Hiranuma N; Otsuka Y; Morino Y
    Can J Cardiol; 2019 Nov; 35(11):1513-1522. PubMed ID: 31679621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
    Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
    J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.
    Grasso C; Attizzani GF; Patané M; Ohno Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Oct; 168(4):4490-1. PubMed ID: 23890924
    [No Abstract]   [Full Text] [Related]  

  • 10. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.
    Onuma Y; Serruys PW; Perkins LE; Okamura T; Gonzalo N; García-García HM; Regar E; Kamberi M; Powers JC; Rapoza R; van Beusekom H; van der Giessen W; Virmani R
    Circulation; 2010 Nov; 122(22):2288-300. PubMed ID: 20975003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing distorted ABSORB Scaffold in left main during anomalous LMCA stenting.
    Rath PC; Reddy KC; Agarwala MK; Purohit BV
    Indian Heart J; 2015; 67(3):268-70. PubMed ID: 26138187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy.
    Yahagi K; Virmani R; Kesavamoorthy B
    Cardiovasc Interv Ther; 2017 Jan; 32(1):53-55. PubMed ID: 26521263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.
    Farooq V; Serruys PW; Heo JH; Gogas BD; Onuma Y; Perkins LE; Diletti R; Radu MD; Räber L; Bourantas CV; Zhang Y; van Remortel E; Pawar R; Rapoza RJ; Powers JC; van Beusekom HM; Garcìa-Garcìa HM; Virmani R
    JACC Cardiovasc Interv; 2013 May; 6(5):523-32. PubMed ID: 23702016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healing responses after bifurcation stenting with the dedicated TRYTON Side-Branch Stent™ in combination with XIENCE-V™ stents: a clinical, angiography, fractional flow reserve, and optical coherence tomography study: the PYTON (Prospective evaluation of the TRYTON Side-Branch Stent™ with an additional XIENCE-v™ everolimus-eluting stent in coronary bifurcation lesions) study.
    Dubois C; Adriaenssens T; Ughi G; Wiyono S; Bennett J; Coosemans M; Ferdinande B; Sinnaeve P; D'hooge J; Desmet W
    Catheter Cardiovasc Interv; 2013 Feb; 81(3):E155-64. PubMed ID: 22745031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incomplete stent apposition and very late stent thrombosis after everolimus eluting stent implantation and dual antiplatelet therapy interruption. A case of OCT guided therapy.
    Gatto P; Dumonteil N; Boudou N; Van Rothem J; Lhermusier T; Bartorelli A; Carrié D
    Int J Cardiol; 2015 Feb; 180():52-4. PubMed ID: 25438210
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
    Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-man unprotected left main stenting with Stentys Xposition S self-apposing sirolimus eluting stent and optical coherence tomography guidance: The emerging panacea for left main intervention.
    Yew KL; Kang Z
    Int J Cardiol; 2015 Dec; 201():628-30. PubMed ID: 26340130
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.
    Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R
    EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.